The US Department of Agriculture approved the genetically modified purple tomato to extend its shelf life and boost nutritional quality almost 15 years after its development.
According to biochemist Cathie Martin, she and her colleagues at Norfolk Plant Scientists (NPS) have been experimenting with pigment production in flowering plants for over two decades, and they've spent almost 15 months developing the purple tomato.
The NPS has been focusing on anthocyanins, the antioxidant-rich pigments that give blackberries and blueberries their signature shades.
Domesticated tomatoes already have genes to produce anthocyanins, but they are not 'turned on.' By carefully adding two genes, the tomatoes and juice become a rich source of antioxidants, because purple pigments are made in the whole tomato, not just the skins.
While there are already some purple-skinned tomatoes, their pigments mostly stop at the outer layers and don't accumulate in the fruit itself.
The NPS also emphasized that there is increasing evidence to show that antioxidants work much better when consumed within foods.
The USDA Animal and Plant Health Inspection Service (APHIS) reported that the tomato was modified to alter its color and enhance its nutritional quality, adding that the plant is unlikely to pose an increased plant pest risk compared to other cultivated tomatoes.
Nathan Pumplin, the CEO of NPS' US-based commercial business, said they are optimistic that they can begin limited distribution of purple tomatoes in the US by 2023.


Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval
Rubio Discusses Iran Crisis and Strait of Hormuz Disruptions With UK and Australia
Gold Prices Hold Firm as Traders Watch U.S.-Iran Ceasefire and Trump-Xi Talks
Norway Core Inflation Hits 3.2% in April, Fueling Interest Rate Hike Expectations
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide
US Stock Futures Hold Steady Ahead of CPI Data and Iran Conflict Concerns
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine
Trump Administration Seeks Court Pause to Reinstate 10% Global Tariffs
Novo Nordisk Shares Tumble After CagriSema Misses Key Trial Endpoint
Armani Group Eyes Strategic Stake Sale to Luxury Giants
NASA and Roscosmos Chiefs Meet in Florida to Discuss Moon and ISS Cooperation
OCBC Q1 Profit Rises 5% on Strong Wealth Management and Non-Interest Income
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment
Trump Says Iran Ceasefire Near Collapse as Oil Prices Surge 



